Navigation Links
SuperNova Diagnostics® Selected to Present at Launch: Silicon Valley 2011
Date:5/25/2011

WASHINGTON, LONDON and HONG KONG, May 25, 2011 /PRNewswire/ -- SuperNova Diagnostics®, Inc., a privately-held global diagnostics company for human and non-human health applications, today announced it has been selected to present at The Silicon Valley Association of Startup Entrepreneurs (SVASE) annual Launch: Silicon Valley 2011 at Microsoft's Mountain View, California campus on Tuesday, June 7, 2011 at 1:15 p.m. PDT.  The presentation will include an overview of SuperNova's proprietary point-of-care (POC) and point-of-use (POU) diagnostic technology targeting four industry sectors: human health, animal health, industrial and biodefence/biosecurity.

"We are honored to be selected as one of 30 innovative companies chosen from more than 300 applicants to present at Launch: Silicon Valley 2011," said Neil J. Campbell, president and CEO of SuperNova Diagnostics.  "This recognition is an example of the dedication of the SuperNova team."

Launch: Silicon Valley 2011 will feature emerging companies in the fields of information technology, mobility, digital media, next generational Internet, life sciences and clean tech.  

About SuperNova Diagnostics®, Inc.

SuperNova® is a development-stage diagnostics company with a proprietary platform for conducting diagnostics at the site of interest with point-of-care in human health and point-of-use for non-human health applications.  A powerful proprietary nanochemistry, AmpCrystal®, can deliver novel, next generation performance for pathogens, proteins, and directly measure DNA without PCR with ultra-low sensitivity and specificity while not sacrificing a dynamic range of measurements.  SuperNova can be utilized in a wide range of diagnostic formats (lateral flow, self-contained cartridges, microtitre, microarrays, closed systems, research products and OEM). SuperNova® — Putting the Laboratory in the Palm of Your Hand®.  For additional information, please visit www.supernovadiagnostics.com.

About The Silicon Valley Association of Startup Entrepreneurs (SVASE)

Founded in 1995 by entrepreneurs, for entrepreneurs, The Silicon Valley Association of Startup Entrepreneurs (SVASE) is the largest and fastest growing nonprofit in Northern California dedicated exclusively to helping technology and life science entrepreneurs start and grow successful businesses.

SVASE provides support and resources for entrepreneurs, from the idea through initial rounds of funding to product launch, delivered at 12 monthly events and a continually evolving web site.  For more information about SVASE, please visit www.svase.org.

For more information on Launch: Silicon Valley 2011, please visit http://www.launchsiliconvalley.org.

Media Contacts:
Tiberend Strategic Advisors, Inc.
(212) 827-0020
Farrell Denby, fdenby@tiberend.com
or
Madeleine Desmond, mdesmond@tiberend.com


'/>"/>
SOURCE SuperNova Diagnostics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. SuperNova Diagnostics® Announces Agreement with KSB Diagnostics of China to Commercialise Neopterin Diagnostics
2. Quest Diagnostics® Care360™ EHR Receives ONC-ATCB 2011/2012 Certification
3. Conflict of Interest Management System Selected by Henry Ford Health System
4. Honeywells Envergent Technologies Selected by Malaysian Company for Renewable Energy Project
5. RRD Selected as Development Partner for NIH Therapeutics for Rare and Neglected Diseases Program
6. Angiotech Pharmaceuticals, Inc. Releases Selected Projected Financial Information
7. CSA Medical Selected to Present at Mid-Atlantic Bio Conference
8. PMC BioTec Selected as a GoingGreen Silicon Valley 100 Winner
9. PROLOR Biotechs Longer-Acting Human Growth Hormone Data Selected for Presentation at 5th International Congress Of The Growth Hormone Research Society and IGF Society
10. Honeywell UOP Technology Selected to Support Conversion of Biomass to Fuel at California Renewable Energy Facility
11. Ion Torrent Selected as World Economic Forum Technology Pioneer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2017)... ... ... Mitotech S.A, a Luxembourg based clinical stage biotechnology company, announced positive results of ... devastating genetic disease that leads to a sudden and rapid loss of central vision. ... 11778, 14484 and 3460 mutations and having experienced the onset of symptoms more than ...
(Date:4/27/2017)... ... April 27, 2017 , ... ... rebrand and a name change to Fluence Analytics. , Fluence Analytics ... of polymer and biopharmaceutical manufacturing processes and R&D applications. The company’s patented ...
(Date:4/26/2017)... ... April 26, 2017 , ... Looking ... team-building and cooking events company, offers one-of-a-kind gifts, ranging from gourmet cooking experiences ... California cuisine, and guests leave inspired with new cooking tips and techniques, thanks ...
(Date:4/26/2017)... ... April 26, 2017 , ... NextSteps 2017, NetDimensions’ annual global ... this May on the following dates: , ?    London, UK from May 10-11, ... Learning and Performance Institute will be the opening keynote speaker at the ...
Breaking Biology Technology:
(Date:4/5/2017)... 2017  The Allen Institute for Cell Science today ... one-of-a-kind portal and dynamic digital window into the human ... first application of deep learning to create predictive models ... and a growing suite of powerful tools. The Allen ... future publicly available resources created and shared by the ...
(Date:3/30/2017)... , March 30, 2017  On April 6-7, ... Hack the Genome hackathon at Microsoft,s headquarters ... two-day competition will focus on developing health and wellness ... Hack the Genome is the first ... tremendous. The world,s largest companies in the genomics, tech ...
(Date:3/27/2017)... , March 27, 2017  Catholic Health ... and Management Systems Society (HIMSS) Analytics for achieving ... Adoption Model sm . In addition, CHS previously ... U.S. hospitals using an electronic medical record (EMR). ... its high level of EMR usage in an ...
Breaking Biology News(10 mins):